Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Cross

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
JAMA|June 11, 2026
Where the Heron FliesSamuel Cross
Open Forum Infectious Diseases|July 10, 2024
Lower Prevalence Countries Outside of South-Eastern Africa Now Have the Fastest Growing HIV EpidemicToby Pepperrell, Andrew Hill, Samuel Cross
BMJ (Clinical Research Ed.)|July 1, 2026
Health costs of the UK-US trade deal on pharmaceuticalsSamuel Cross, Karl Claxton, Andrew Hill
Open Forum Infectious Diseases|January 12, 2023
Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIVToby Pepperrell, Samuel Cross, Andrew Hill
AIDS (London, England)|April 1, 2026
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countriesSamuel Cross, Jacob Levi, Francois Venter, et al.
BMJ Global Health|December 23, 2021
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?Samuel Cross, Yeanuk Rho, Henna Reddy, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
JAMA|June 11, 2026
Where the Heron FliesSamuel Cross
Open Forum Infectious Diseases|July 10, 2024
Lower Prevalence Countries Outside of South-Eastern Africa Now Have the Fastest Growing HIV EpidemicToby Pepperrell, Andrew Hill, Samuel Cross
BMJ (Clinical Research Ed.)|July 1, 2026
Health costs of the UK-US trade deal on pharmaceuticalsSamuel Cross, Karl Claxton, Andrew Hill
Open Forum Infectious Diseases|January 12, 2023
Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIVToby Pepperrell, Samuel Cross, Andrew Hill
AIDS (London, England)|April 1, 2026
The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countriesSamuel Cross, Jacob Levi, Francois Venter, et al.
BMJ Global Health|December 23, 2021
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?Samuel Cross, Yeanuk Rho, Henna Reddy, et al.
Pageof 1